Alaunos Therapeutics (TCRT) Current Deferred Revenue (2009 - 2018)
Alaunos Therapeutics' (TCRT) quarterly Current Deferred Revenue came in at $13000.0 in Q4 2018, down 99.97% YoY from $41.5 million in Q4 2017, and down 99.97% on a QoQ basis from $49.5 million in Q3 2018.
Alaunos Therapeutics (TCRT) Current Deferred Revenue (2009 - 2018) Analysis & Trends
Alaunos Therapeutics (TCRT) has 10 years of Current Deferred Revenue data on file, last reported at $13000.0 in Q4 2018.
- Quarterly Current Deferred Revenue fell 99.97% year-over-year to $13000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $13000.0 (down 99.97% YoY) and the FY2018 annual result came in at $13000.0, down 99.97% from the prior year.
- Current Deferred Revenue declined to $13000.0 in Q4 2018, from $49.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $49.5 million in Q3 2018 to a low of $13000.0 in Q4 2018.
- A 5-year average of $6.6 million and a median of $952000.0 in 2015 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 29719.28% in 2018, down 99.97% in 2018.
- Tracing TCRT's Current Deferred Revenue over 5 years: stood at $280000.0 in 2014, then surged by 2350.36% to $6.9 million in 2015, then tumbled by 97.74% to $155000.0 in 2016, then soared by 26674.19% to $41.5 million in 2017, then slumped by 99.97% to $13000.0 in 2018.
- The last three Current Deferred Revenue figures came in at $13000.0 (Q4 2018), $49.5 million (Q3 2018), and $63000.0 (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | 49.50 Mn |
| Jun 30, 2018 | 63,000.00 |
| Mar 31, 2018 | 476,000.00 |
| Dec 31, 2017 | 41.50 Mn |
| Sep 30, 2017 | 166,000.00 |
| Jun 30, 2017 | 6.39 Mn |
| Mar 31, 2017 | 6.39 Mn |
| Dec 31, 2016 | 155,000.00 |
| Sep 30, 2016 | 177,000.00 |
| Jun 30, 2016 | 223,000.00 |
| Mar 31, 2016 | 6.49 Mn |
| Dec 31, 2015 | 6.86 Mn |
| Sep 30, 2015 | 6.93 Mn |
| Jun 30, 2015 | 816,000.00 |
| Mar 31, 2015 | 1.09 Mn |
| Dec 31, 2014 | 280,000.00 |
| Sep 30, 2014 | 1.70 Mn |
| Jun 30, 2014 | 2.33 Mn |
| Mar 31, 2014 | 224,000.00 |